(firstQuint)A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma.

 This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose, dose-escalation, safety, PK, and PD study of ALX148.

 The phase 1 protocol will have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2).

 Part 2 will include an initial dose escalation portion followed by a dose expansion portion.

 Approximately 142 adult patients are expected to be enrolled in the study.

.

 A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma@highlight

A phase 1, dose escalation study of ALX148 in patients with advanced solid tumors and lymphoma